ISRCTN11464134 https://doi.org/10.1186/ISRCTN11464134

Phase I Trial: Quotient Code QSC302899

Submission date 26/03/2025	**Recruitment status** No longer recruiting	[X] Prospectively registered [_] Protocol
Registration date 28/03/2025	**Overall study status** Deferred	[_] Statistical analysis plan [_] Results
Last Edited 30/04/2025	**Condition category** Other	[_] Individual participant data [X] Record updated in last year

Plain English summary of protocol
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)
Public, Scientific

Contact name
Ms Cornelia Krueger

Contact details
Shionogi B.V.
Herengracht 464
Amsterdam
Netherlands
1017 CA
+44 (0)20 3053 4200
regulatory.affairs@shionogi.eu

Type(s)
Principal Investigator

Contact name
Dr Nand Singh

Contact details
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham

United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number
1011191

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Quotient Code: QSC302899

Study information

Scientific Title
Phase I Trial: Quotient Code QSC302899

Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 11/04/2025, London - Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 (0)20 7104 8057; surreyborders.rec@hra.nhs.uk), ref: 25/LO/0024

Study design
Absorption metabolism distribution and elimination (ADME) study

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
Pharmaceutical testing facility

Study type(s)

Other

Participant information sheet
Not available in web format

Health condition(s) or problem(s) studied
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Intervention Type
Drug

Pharmaceutical study type(s)
Pharmacokinetic

Phase
Phase I

Drug/device/biological/vaccine name(s)
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Primary outcome measure
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Secondary outcome measures
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Overall study start date
11/02/2025

Completion date
08/07/2025

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)
Healthy volunteer

Age group
Adult

Lower age limit
30 Years

Upper age limit
65 Years

Sex
Male

Target number of participants
7

Key exclusion criteria
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment
15/04/2025

Date of final enrolment
08/07/2025

Locations

Countries of recruitment
England

United Kingdom

Study participating centre
Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS

Sponsor information

Organisation
Shionogi B.V.

Sponsor details
Herengracht 464
Amsterdam
Netherlands
1017 CA
+44 (0)20 3053 4200
regulatory.affairs@shionogi.eu

Sponsor type
Industry

Website
https://www.shionogi.com/eu/en/

Funder(s)

Funder type
Industry

Funder Name
Shionogi B.V.

Results and Publications

Publication and dissemination plan
Full trial details will be published up to 30 months after the end of the trial. Publication of some of the trial details is deferred because of the high commercial sensitivity of this Phase I study and the negligible benefit to the public of Phase I information. Results may be posted on or after the date of publication of trial details.

Intention to publish date
08/01/2028

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available